Block listing Interim Review

RNS Number : 4049R

Aptamer Group PLC

28 February 2023

 

28 February 2023

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Block Listing Interim Review

Aptamer Group plc (AIM: APTA), the developer of novel Optimer ^®  binders to enable innovation in the life sciences industry, makes the following notification p ursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies regarding its existing block admission:

Name of Company	Aptamer Group plc
Name of Scheme	The Aptamer Group EMI Share Option Scheme
Period of Return (from/to)	25 August 2022 to 24 February 2023
Number and class of securities not issued at the start of the period under the scheme	1,792,400 Ordinary Shares
Number of securities issued under the scheme during the period	34,123
Options waived and not to be exercised	91,800
Balance under the scheme of securities not yet issued at the end of the period	1,666,477
Number and class of securities originally admitted and the date of admission	2,063,200 Ordinary Shares on 25 February 2022
Name of contact and telephone number	Jenny Cutler [phone]

- ENDS -

For further information, please contact:

Aptamer Group plc	[phone]
Dr Arron Tolley - CEO
SPARK Advisory Partners Limited - Nominated Adviser	[phone]
Andrew Emmott / Mark Brady / Adam Dawes
Liberum Capital Limited - Broker	[phone]
Richard Lindley / Ben Cryer / Cara Murphy
Consilium Strategic Communications	[phone]
Matthew Neal / Chris Welsh / Lucy Featherstone

[e-mail]

About Aptamer Group plc

Aptamer   Group   develops custom affinity binders through its proprietary Optimer ^®  platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145bn. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.

 

END

 

 

BLRDVLFLXLLZBBZ